

HaemaLogiX_____

Scientific and Technology Committee Charter

HaemaLogiX Limited
ACN 603 314 496

1. INTRODUCTION

The board of directors (**Board**) of HaemaLogiX Limited (**Company**) has established the Scientific and Technology Committee (**Committee**). This Charter outlines the purpose, composition and responsibilities of the Committee.

2. PURPOSE

The primary purpose of the Committee is to:

- (a) discuss and prepare strategy and recommendations to the Board, regarding the Company's pipeline, research and development strategies, priorities and opportunities that will impact the company's portfolio and support the target product profile (TPP) / desired label claims. This includes all aspects of Product Development – Pre Clinical / Clinical / Regulatory / Commercial across all selected product indications and patient populations;
- (b) advise the Board on key preclinical and/or clinical design approaches to expedite development, achieve and highlight a desirable scientific profile; and
- (c) discuss and provide input regarding business development opportunities identified by the Company.

3. COMMITTEE COMPOSITION

The Committee shall be composed of a minimum of three Board members (including a Chairperson). The Committee members shall have authority to delegate its responsibilities to a subcommittee of, or individual members of, the Company, if the Committee determines such delegation would be in the best interests of the Company.

4. COMMITTEE MEETING REQUIREMENTS

- (a) The Committee shall meet as necessary to enable it to fulfill its responsibilities, estimated to be monthly, but at least 4 times, within each 12-month period. Each Committee meeting will be scheduled either for a minimum of 1 hour. Ad hoc meetings of any duration may be called as needed.
- (b) The quorum is at least 2 Committee members present, either in person or by using technology.
- (c) The Chairperson of the Committee, together with the Chief Scientific Officer (**CSO**), shall be responsible for preparing the agenda and identifying the key goals and objectives to be addressed at each meeting. They will also preside over Committee meetings and agree to a summary of minutes of each Committee meeting for circulation to and discussion with all Board Members.
- (d) Notice will be given to every member of the Committee, of every meeting of the Committee. However, there is no minimum notice period and acknowledgement of receipt of notice by all members is not required before the meeting may be validly held.
- (e) The Committee may ask members of management or others whose advice and counsel are relevant to issues being considered by the Committee, to

inform and to provide pertinent information to the Committee that they may need, to be able to make their recommendations.

- (f) The Committee should pursue collective decision-making and seek consensus where possible. The Committee chairperson should test consensus and, if a unanimous view cannot be reached, decisions will be based on a majority view.
- (g) Each Committee Meeting will begin by reviewing and agreeing to any changes to the strategy of the company relevant to the scientific plans of the Company and seek input from members of the Company's Scientific Advisory Board (**SAB**) and relevant Company staff on such changes.
- (h) Each Committee Meeting will close by providing a brief summary of the decisions and actions to be taken by the Company, including the rationale for such decisions, including SAB recommendations.

5. COMMITTEE RESPONSIBILITIES

In carrying out its responsibilities, the Committee should maintain flexibility and be able to react to a changing competitive landscape and new evolving scientific knowledge relevant to the Company's products. Accordingly, the Committee may:

- (a) provide strategic advice and confirm strategic approach to the Board Members regarding current and planned research and development programs;
- (b) consider recommendations from SAB, regarding the scientific merit of technology or products involved in licensing and acquisition opportunities and re-evaluate and confirm Company direction and approach accordingly;
- (c) consider strategic advice from SAB and external consultants, regarding emerging science and technology issues and evolving trends related to the company's products and strategies and re-evaluate and confirm Company direction and approach accordingly;
- (d) occasionally on an ad hoc basis, request the support of SAB members or external consultants, subject to their availability, in discussions with regulators or to consider specific scientific matters pertinent to their expertise.

6. REVIEWS

- (a) The Committee is responsible for:
 - (i) reviewing the effectiveness of this Charter and the operations of the Committee; and
 - (ii) making recommendations to the Board of any amendments to this Charter.
- (b) The Committee shall review its performance on an annual basis.

7. APPROVED AND ADOPTED

This Charter was approved by the Board on 9 July 2025 and adopted from that date.